Open Access
Subscription Access
Open Access
Subscription Access
Bioavailability study of Kankasava
Subscribe/Renew Journal
Bioavailability was assessed by determining the maximum (peak) plasma drug concentration of kankasava. Blank plasma gave no interfering peak at the retention time of piperine making the analysis very simple. In the plasma concentration - time profile of kankasava formulation in rats (n=6) piperine could be detected in plasma from 0.5 to 8 hours after administration with maximum plasma concentration (2.80 - 1.76 μg/ml) at 0.5 - 1 h post dosing.
Subscription
Login to verify subscription
User
Font Size
Information
- Bajad S, Bedi K L, Singh A K and Johri R K. Planta Med, 2001, 67; 176.
- Bajad S, Coumer M, Khajuria R, Suri OP and Bedi KL. Characterization of new urinary metabolites of piperine by LC/NMR/MS studies, European J Pharmaceutical Sciences, 2003, (19(5); 413-421.
- EMEA–The European Agency for the Evaluation of Medicinal Products–Evaluation of Medicine for Human Use, London, 2001.
- Guidance for Industry: Bioavailability and bioequivalence studies for orally administered drug products-General considerations, U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2002.
- Zhixiu L, Hoult J R S, Benett DC and Raman A. Planta Med, 1999, 65: 600.
Abstract Views: 859
PDF Views: 1